{"id":97537,"date":"2019-10-17T07:44:15","date_gmt":"2019-10-17T14:44:15","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2019\/10\/epibone-inc-receives-fda-clearance-to-commence-its-first-in-human-phase-1-2-trial-of-its-bone-product-eb-cmf"},"modified":"2019-10-17T07:44:15","modified_gmt":"2019-10-17T14:44:15","slug":"epibone-inc-receives-fda-clearance-to-commence-its-first-in-human-phase-1-2-trial-of-its-bone-product-eb-cmf","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2019\/10\/epibone-inc-receives-fda-clearance-to-commence-its-first-in-human-phase-1-2-trial-of-its-bone-product-eb-cmf","title":{"rendered":"EpiBone, Inc. Receives FDA Clearance to Commence its First-In-Human, Phase 1\/2 Trial of its Bone Product, EB-CMF"},"content":{"rendered":"<p><a class=\"blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/epibone-inc-receives-fda-clearance-to-commence-its-first-in-human-phase-1-2-trial-of-its-bone-product-eb-cmf.jpg\"><\/a><\/p>\n<p><i>Potential breakthrough technology for stem-cell based bone replacement<\/i><\/p>\n<p>NEW YORK, May 22, 2019 \/PRNewswire\/ \u2014 EpiBone, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted its Investigational New Drug (IND) clearance to proceed with a Phase 1\/2 clinical trial of its lead bone product EpiBone-Craniomaxillofacial (EB-CMF), as a potential treatment for ramus continuity defects in the mandible. The ramus is a key component of the jaw bone which attaches to the muscles associated with chewing.<\/p>\n<p>EB-CMF is a living anatomically correct bone graft manufactured from a patient\u2019s own adipose derived stem cells. This eliminates the need to harvest bone from a patient\u2019s body, potentially reducing pain, surgical and hospitalization time while creating a precision fit with the defect.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Potential breakthrough technology for stem-cell based bone replacement NEW YORK, May 22, 2019 \/PRNewswire\/ \u2014 EpiBone, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted its Investigational New Drug (IND) clearance to proceed with a Phase 1\/2 clinical trial of its lead bone product EpiBone-Craniomaxillofacial (EB-CMF), as a potential treatment for [\u2026]<\/p>\n","protected":false},"author":367,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1522],"tags":[],"class_list":["post-97537","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-innovation"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/97537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/367"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=97537"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/97537\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=97537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=97537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=97537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}